[31] In a multi-center study among hemodialysis patients, 4 of 123 patients discontinued DCV + ASV therapy because of elevated serum alanine transaminase levels (n = 2), rash (n = 1), and HCC; all of these achieved SVR12. This evidence concerns the gene GPT and hepatocellular carcinoma.